Venom Allergy Testing Report

Report Status: [Final / Preliminary] (Mark "Preliminary" only if confirmatory testing is pending.)

Test Date: [Date testing performed]

Location: [Clinic/site name and setting]

Ordering Clinician: [Name and reason for referral]

Performing Clinician: [Name and credentials]

Patient: [Full name, DOB, MRN]

Indication

[Clinical question for testing] (Include the approximate date of the index sting event and reason testing is being performed now—recent reaction, occupational exposure, quality-of-life impairment, or pre-VIT work-up. If the sting date is unknown, note approximately as season/year per patient report. If indication was not clearly provided, document this and note any assumptions discussed with ordering clinician.)

Sting Reaction History

[Index sting event narrative] (Include suspected insect and confidence level [certain / likely / unsure], geographic and situational context, sting location on body, number of stings, and time from sting to symptom onset. Describe symptom progression and maximum severity by organ system: skin/mucosa, respiratory, cardiovascular, gastrointestinal. Document treatments received including epinephrine doses and who administered, ED visit, hospitalization, or ICU admission. Note whether EMS/ED records were reviewed.)

[Prior sting reactions] (Document prior systemic reactions with approximate dates, prior large local reactions, and any tolerance of subsequent stings after the index event.)

(If interpreting externally obtained results without clinical reaction history, state: Clinical reaction history was not available; interpretation is limited accordingly.)

Relevant Medical History

• Asthma: [present and control status / absent / not assessed]
• Cardiovascular disease: [present / absent / not assessed]
• Features suggestive of mast cell disorder: [present / absent / not assessed]
• Baseline serum tryptase: [value if known / not obtained]
• Prior venom immunotherapy: [venoms, duration, reason stopped, reactions / none / unknown]
• Medications affecting anaphylaxis management: [beta-blockers, ACE inhibitors if present / none]
• Exposure risk: [high / moderate / low] [brief description]

Pre-Test Preparation

(Include only when skin testing was performed. If only serum testing was performed, omit this section.)

• Medications held: [medications and duration of hold]
• Medications complicating anaphylaxis management: [beta-blockers, ACE inhibitors and risk discussion / none]
• Consent: [obtained / discussion points if notable]
• Clinical stability: [stable for testing / concerns noted]
• Observation plan: [duration and location]

Testing Methods

• Modalities: [skin prick testing / intradermal testing / serum venom-specific IgE / component testing / baseline serum tryptase] (List all performed.)
• Venoms tested: [list venoms and rationale if not comprehensive panel] (Typical: honeybee, yellow jacket, hornet, paper wasp, fire ant when indicated.)
• Skin prick testing: [extract concentrations, reading time in minutes]
• Intradermal testing: [concentration step-up scheme, maximum concentration, reading time in minutes]
• Controls: Histamine [wheal/erythema mm], Saline [wheal/erythema mm] (Comment on test validity.)
• Serum testing: [assay platform if known, specimen collection date relative to sting]
• Positivity criteria: [skin prick threshold, intradermal threshold, serum sIgE interpretation] (Note: positive tests indicate sensitization and must be interpreted in clinical context.)
• Adverse events: [symptoms, treatment, disposition / none]

Test Results

Venom	Skin Prick (wheal/erythema mm; concentration)	Intradermal (first positive concentration; wheal/erythema mm)	Serum sIgE (kU/L; date)	Interpretation
[Venom]	[Result / not performed]	[Result / negative to max concentration / not performed]	[Value / not performed]	[sensitized / not sensitized / equivocal]
[Venom]	[Result / not performed]	[Result / negative to max concentration / not performed]	[Value / not performed]	[sensitized / not sensitized / equivocal]

(Add rows as needed. Omit columns for modalities not performed.)

[Notable findings narrative] (Summarize cross-reactive patterns, discordances between skin and serum testing, or other clinically relevant observations. If baseline tryptase was obtained, report value with units and reference range.)

Interpretation

[Test validity assessment] (Comment on control adequacy, timing relative to sting that may reduce sensitivity, and possible medication interference.)

[Sensitization pattern] (Describe predominant honeybee versus vespid sensitization, multiple vespid positives consistent with cross-reactivity, or dual positivity where culprit remains uncertain. If inferring likely culprit, use "most consistent with" and document rationale.)

[Clinical diagnosis statement] (Link history and testing: e.g., findings support IgE-mediated Hymenoptera venom allergy consistent with the documented systemic reaction; or testing shows sensitization without documented systemic reaction and clinical venom allergy is not established.)

Note: Positive results indicate sensitization and require clinical correlation; they do not predict reaction severity.

Recommendations

Venom Immunotherapy

Recommendation: [VIT recommended / VIT not routinely indicated / VIT may be considered with shared decision-making]

[Rationale] (Include reaction severity, sensitization evidence, exposure frequency, comorbidities, quality-of-life impact.)

(If VIT recommended: specify venoms to include with cross-reactivity rationale, build-up approach, target maintenance dose, expected duration, and observation/risk counseling provided.)

(If VIT not recommended: document explicit reasoning and what findings would change the recommendation.)

Emergency Preparedness

• Epinephrine autoinjector: [new prescription / refill / patient declined with rationale]
• Dose: [dose prescribed] (Include recommendation for multiple devices if appropriate.)
• Training: [indications and technique reviewed / anaphylaxis action plan provided]

Follow-Up

• [Follow-up timeline and plan]
• [Pending tests and communication plan]
• [Referrals if indicated]

Patient Counseling

• [Explained sensitization versus allergy and that test magnitude does not predict severity]
• [Benefits and risks of VIT discussed if applicable]
• [Sting avoidance strategies tailored to suspected insect]
• [Patient preferences or concerns expressed]
• [Handouts provided]